Polaris Market Research continuously try to provide quality analysis and market estimation studies to its clients. The new report on 2020 Japan Cancer Vaccines Market analysis, size, share, growth, trends and forecasts, focuses on customers research requirements and try to provide in-depth details on market trends.
The Japan Cancer Vaccines market size is expected to reach USD 1,470.4 Million by 2026 and is anticipated to grow at a CAGR of 17.8% during the forecast period (2020-2026) according to a new study by Polaris Market Research. The report “Japan Cancer Vaccines Market Share, Size, Trends, Industry Analysis Report By Type (Prevention Vaccines, Treatment Vaccines, Oncolytic Viruses); Indication (Prostate, Cervical, Others); By Patient Type (Pediatric, Adult); By Regions, Segments & Forecast, 2020 – 2026” gives a detailed insight into current market dynamics and provides analysis on future market growth.
For several years now, Japan has been experiencing a boom in the incidence of cancer patients. Cancer is one of the major causes of death in Japan. As cancer prevention, the people in Japan mainly follow their traditional low-fat diet which has proven to be effective however, there are certain limitation to this as high salt in the Japanese diet can act as a potential risk for development of stomach cancer. Though Japanese government is promoting various new ways of prevention and treatment of the disease, implementation of cancer vaccines in the healthcare regime is a must and it is necessary for the government to take steps towards usage of these vaccines in Japan.
Request A Sample Report at: https://www.polarismarketresearch.com/industry-analysis/japan-cancer-vaccines-market/request-for-sample
The key players in the market : Aduro BioTech, Inc., Daiichi Sankyo Company, Otsuka Pharmaceutical Co., Ltd., Astellas Pharma, Inc., AstraZeneca PLC, Bristol-Myers Squibb, GlaxoSmithKline, Merck & Co., Inc., tella,Inc., Oncolys BioPharma Inc, CYTLIMIC, BrightPath Biotherapeutics, Takeda Pharmaceutical Company Limited, Takara Bio, Boston Biomedical (acquired by Dainippon Sumitomo Pharma Co., Ltd: DSP), ImmunoFrontier, Inc., OncoTherapy Science, Inc., Regeneus Ltd
The primary factor driving the growth of this market in Japan is the growing rate of prevalence of incidence. According to the National Cancer Registry system, in 2016, around 995,132 new patients were diagnosed with cancer of which 566,575 were men and 428,499 were women. Each year, about 10,000 Japanese women are newly diagnosed with the disease while 3,000 die from it. With growing number of patients there is a rising need for a preventive measure that could help stabilize the increasing rate of incidence. Furthermore, growing government initiatives to generate awareness amongst people, and increasing research and development activities are also fueling the growth of this market in Japan.
For instance, in January 2018 the University of Tokyo signed an agreement with the Kanagawa Cancer Center in Yokohama and BrightPath Biotherapeutics for development of a personalized cancer vaccine using a novel method involving the body’s immune response. Furthermore, in February 2018, Japanese Patent Office issued a decision to grant a patent covering the use of cancer vaccine technology for the treatment of a range of cancers in humans and animals. Such initiatives and research activities are with an aim of improving the cancer vaccine product line in the Japanese market and thus, fuel the growth of this regional segment.
In 2013, HPV vaccines were added to the national vaccine program in Japan. The same year, several complains were registered proving the side effects associated with cancer vaccines in Japan. This was the major reason for the suspended its recommendation and usage in Japanese industry. Before the suspension around 70% of adolescent girls received the immunization as prevention from cervical cancer. However this number dropped to less than 1% after the health ministry suspended its active recommendation after reports of side effects including muscle pain, sleep disorders, and light and sound sensitivity. Furthermore, companies also restrict from opting to manufacture cancer vaccines as it is a time consuming process with high cost of development and initial setup. These and many such factors are expected to hinder the market growth of cancer vaccines in the Japanese industry during the forecast period.
To get Incredible Discounts on this Premium Report, Click At : https://www.polarismarketresearch.com/industry-analysis/japan-cancer-vaccines-market/request-for-discount-pricing
Japanese government and many local and international companies are taking initiatives to develop the cancer vaccine industry in this region. In order to promote and develop regenerative medicine and cell therapy in Japan, the Act on the Safety of Regenerative Medicine and the Revised Pharmaceutical Affairs Law was enforced in November 2014. Also, Advanced Medical Care is accepted in Japan to evaluate a medical technology at one’s own expense, together with the National Health Insurance, at institutes and hospitals approved by the MHLW. The technological intervention includes regenerative medicine and immunotherapy, the safety and efficacy of which have not been established by previous clinical studies.
Furthermore, many companies are conducting clinical trials to develop and launch innovative vaccines that could help the cancer patients. Companies such as Cytlimic, Aduro Biotech, Oncolys BioPharma, and Otsuka are some of them who have initiated many projects focusing on enhancing their cancer vaccine product line. These initiatives have attracted international funding and thus has created significant growth opportunities for established and emerging players in the global and Japanese cancer vaccines market. The key players in the market include Aduro BioTech, Inc., Astellas Pharma, Inc., Bristol-Myers Squibb, tella, Inc., Oncolys BioPharma Inc., CYTLIMIC, Takeda Pharamceutical, and Takara Bio among others.
To customize the study according to your specific requirements please click At : https://www.polarismarketresearch.com/industry-analysis/japan-cancer-vaccines-market/request-for-customization
Table of Contents
Overview and Scope
Market Factor Analysis
Japan Cancer Vaccine Market Assessment by Type
- Prevention Vaccines
- Treatment Vaccines
- Antigen vaccines
- Dendritic cell vaccines
- DNA vaccines
- Whole tumor vaccines
- Anti-idiotype vaccines
- Oncolytic Viruses
Japan Cancer Vaccine Market Assessment by Indication
Japan Cancer Vaccine Market Assessment by Patient Type
List of Tables
Table 1 Drivers and Inhibitors For Japanese Market
Table 2 Restraints Japanese Market
Table 3 Japan Cancer Vaccine Market, By Type, 2017 – 2026 (USD Million)
Table 4 Japan Prevention Vaccine Market, by Type, 2017-2026 (USD Million)
List of Figures
Figure 1. Market Highlights
Figure 2. Integrated Ecosystem
Figure 3. Research Methodology: Top Down Approach
Figure 4. Research Methodology: Bottom Up Approach
To gain more insights into the market with detailed table of content and figures, click here: https://www.polarismarketresearch.com/industry-analysis/japan-cancer-vaccines-market/toc
The report can be customized on the basis of regional analysis, segment analysis, industry outlook and competitive analysis. Some of the major focus points which are covered in the report include:
- Industry Trends, opportunity and challenges in the market
- Role of key players across the value chain
- End-User analysis to define the market strategy
- Competitive mapping
- Regional and country level breakdown
These insights are included in the report which would help you to have a realistic overview of the overall market including the competition, investment opportunities, restraints and challenges, regulatory factors which might affect the market growth. Moreover, the report would help to identify the regional market growth opportunities for different segments covered in the report.
Buy Now this Premium Report to Grow your Business @ https://www.polarismarketresearch.com/checkouts/6471
About Polaris Market Research
Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for our clientele spread across different enterprises. We at Polaris are obliged to serve our diverse customer base present across the industries of healthcare, technology, semi-conductors and chemicals among various other industries present around the world. We strive to provide our customers with updated information on innovative technologies, high growth markets, emerging business environments and latest business-centric applications, thereby helping them always to make informed decisions and leverage new opportunities. Adept with a highly competent, experienced and extremely qualified team of experts comprising SMEs, analysts and consultants, we at Polaris endeavour to deliver value-added business solutions to our customers.
Polaris Market Research